Trial Profile
An Open Label Study to Investigate the Role of Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis With CFTR Dysfunction
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 18 Feb 2022
Price :
$35
*
At a glance
- Drugs Ivacaftor (Primary)
- Indications Chronic bronchitis
- Focus Therapeutic Use
- 01 Feb 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Feb 2022.
- 01 Feb 2022 Status changed from recruiting to withdrawn prior to enrolment.
- 28 Jun 2021 Planned primary completion date changed from 1 Jan 2021 to 1 Jan 2022.